Swedish Orphan Biovitrum
SOBI | ST
Overview
Corporate Details
- ISIN(s):
- SE0000872095 (+51 more)
- LEI:
- 549300124Y3MQI87PT35
- Country:
- Sweden
- Address:
- Tomtebodavagen 23A, 112 76 Stockholm
- Website:
- https://www.sobi.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Swedish Orphan Biovitrum.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-16 08:00 |
Quarterly Report
|
Swedish | 4.1 MB | |
| 2025-07-16 08:00 |
Earnings Release
|
English | 4.1 MB | |
| 2025-07-15 19:15 |
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
|
English | 138.4 KB | |
| 2025-07-15 19:15 |
Transaction in Own Shares
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åt…
|
Swedish | 137.1 KB | |
| 2025-07-01 13:00 |
M&A Activity
Sobi uppdaterar avtalet med Apellis om royalty på Aspaveli® (systemisk pegcetac…
|
Swedish | 193.0 KB | |
| 2025-07-01 13:00 |
M&A Activity
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli…
|
English | 202.6 KB | |
| 2025-06-28 00:55 |
Regulatory News Service
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…
|
English | 227.3 KB | |
| 2025-06-28 00:55 |
Earnings Release
FDA godkänner Gamifant® (emapalumab-lzsg) som den första behandlingen för vuxna…
|
Swedish | 244.4 KB | |
| 2025-05-08 11:30 |
Post-Annual General Meeting Information
Kommuniké från Sobis årsstämma
|
Swedish | 148.7 KB | |
| 2025-05-08 11:30 |
Post-Annual General Meeting Information
Bulletin from Sobi’s Annual General Meeting (AGM)
|
English | 158.7 KB | |
| 2025-04-29 08:00 |
Quarterly Report
|
Swedish | 4.1 MB | |
| 2025-04-29 08:00 |
Quarterly Report
|
English | 4.1 MB | |
| 2025-02-05 08:01 |
Earnings Release
|
Swedish | 4.1 MB | |
| 2025-02-05 08:01 |
Earnings Release
|
English | 4.0 MB | |
| 2025-01-10 18:00 |
Earnings Release
Sobis intäkter för helåret 2024 högre än tidigare uppskattningar
|
Swedish | 144.9 KB |
Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | Katy Mazibuko | Other | Sell | 1,500 | 480,000.00 SEK |
| 2024-08-30 | Katy Mazibuko | Other | Sell | 269 | 86,012.75 SEK |
| 2024-08-12 | Sara Karlsson | Other | Buy | 86 | 23,391.79 SEK |
| 2024-07-25 | Mahmood Ladha | Other | Buy | 84,585 | 12,360,406.05 SEK |
| 2024-07-23 | Mahmood Ladha | Other | Sell | 84,585 | 24,614,235.00 SEK |
| 2024-06-10 | Christin Wesström | Other | Other | 7,433 | N/A |
| 2024-06-03 | Guido Oelkers | Other | Buy | 117,332 | 23,965,061.00 SEK |
| 2024-05-30 | Guido Oelkers | Other | Sell | 117,332 | 32,090,302.00 SEK |
| 2024-05-15 | Henrik Stenqvist | Other | Buy | 72,534 | 14,815,069.50 SEK |
| 2024-05-13 | Henrik Stenqvist | Other | Sell | 72,534 | 20,766,484.20 SEK |
